NCT04784442View on ClinicalTrials.gov

A Dose-finding Trial of ETC-1002(Bempedoic Acid) in Patients With Hypercholesterolemia

PHASE2CompletedINTERVENTIONAL
Enrollment

188

Participants

Timeline

Start Date

March 24, 2021

Primary Completion Date

April 18, 2022

Study Completion Date

May 17, 2022

Conditions
Hypercholesterolemia
Interventions
DRUG

180mg of ETC-1002(bempedoic acid)

180mg, tablet, once daily, for 12 weeks

DRUG

120mg of ETC-1002(bempedoic acid)

120mg, tablet, once daily, for 12 weeks

DRUG

60mg of ETC-1002(bempedoic acid)

60mg, tablet, once daily, for 12 weeks

DRUG

Placebo

placebo, tablet, once daily, for 12 weeks

Trial Locations (1)

Unknown

Tokyo-Eki Center-Building Clinic, Chuo-ku,Tokyo

Sponsors
All Listed Sponsors
lead

Otsuka Pharmaceutical Co., Ltd.

INDUSTRY